# Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Canonical URL: https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2437a21b
Ticker: NKTR
Company: Nektar Therapeutics
Source: Nektar Therapeutics
Published: 2026-06-26 20:30 EST
Original Source URL: https://ir.nektar.com/news-releases/news-release-details/nektar-therapeutics-reports-inducement-grants-under-nasdaq-4
## Summary

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and

## Article Body
SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 20,500 shares of its common stock and
## Recent Company News
- 2026-06-26 20:30 EST — [Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-2437a21b) — Source: Nektar Therapeutics
- 2026-06-25 13:46 EST — [Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-new-york) — Source: Nektar Therapeutics
- 2026-06-25 13:46 EST — [Nektar Therapeutics Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-first-quarter-2026-financial-results) — Source: Nektar Therapeutics
- 2026-06-25 13:46 EST — [Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/NKTR/nektar-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Nektar Therapeutics
- 2026-06-25 13:46 EST — [Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting](https://biopharmsignal.com/news/NKTR/data-from-phase-2b-studies-for-rezpegaldesleukin-accepted-for-two-oral-presentations-at-the-2026-american-academy-of-dermatology-annual-meeting) — Source: Nektar Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)